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Abstract
Dedifferentiated liposarcoma (DDL) is a
histologically pleomorphic sarcoma, tradition-
ally defined as well-differentiated liposarcoma
with abrupt transition to high grade, non-
lipogenic sarcoma. It can occur as part of
recurrent well-differentiated liposarcoma, or
may arise de novo. DDL most frequently occurs
within the retroperitoneum, and while it is
prone to local recurrence, it usually has a lower
rate of metastasis than other pleomorphic sar-
comas. We describe a case of retroperitoneal
dedifferentiated liposarcoma in a 63-year-old
male, who showed MDM2 amplification with
fluorescence in situ hybridization, which dis-
played unusually aggressive behavior, with
brain, lung and subcutaneous soft tissue
metastases. As previous reports of metastatic
liposarcoma have largely grouped DDL in with
other (genetically and clinically distinct)
liposarcoma subtypes, we highlight and dis-
cuss the rare occurrence of brain metastasis in
MDM2-amplified retroperitoneal liposarcoma.
Introduction
Dedifferentiated liposarcoma (DDL) is tra-
ditionally defined as well-differentiated
liposarcoma (WDL) with abrupt transition to
high grade, non-lipogenic sarcoma, either in
primary or recurrent tumor. Most DDL (80-
90%) occur de novo. Secondary dedifferentia-
tion occurs in approximately 10% of cases and
seems to be associated with multiple recur-
rences of well-differentiated liposarcoma.1-3
Dedifferentiated liposarcoma has a lower ten-
dency to local recurrence and metastasis, com-
pared with both other liposarcoma subtypes
(myxoid liposarcoma and pleomorphic liposar-
coma), which are genetically and clinically dis-
tinct.4 Retroperitoneal DDL is a biologically
heterogeneous neoplasm, which presents con-
siderable treatment challenges due to its deep
location and size at the time of diagnosis.
While it has a tendency to recur following sur-
gical excision, often repeatedly, metastasis of
DDL outside the abdominal cavity is very rare.1
We describe a case of DDL that metastasized to
the soft tissues, lung and brain. This pattern of
metastatic disease, and in particular brain
metastasis of DDL is exceptionally rare, and
expands the documented behavioral spectrum
of this heterogeneous neoplasm. 
Case Report
A 63-year-old male presented with a history
of progressive abdominal distension and
abdominal pain. Computed tomography (CT)
scan showed a 28×20 cm fatty mass expanding
the right retroperitoneum, extending from the
subhepatic space into the right pelvis, and dis-
placing the kidney superiorly. Inferiorly there
was a 12×11 cm solid, focally calcified compo-
nent and a 5 cm solid nodule invading mesen-
teric fat and containing soft tissue stranding,
as well as several smaller peripheral solid soft
tissue nodules. There was no evidence of dis-
ease elsewhere in the chest, abdomen or
pelvis. The radiological impression was of a
large right-sided retroperitoneal well-differen-
tiated liposarcoma with multiple dedifferenti-
ated components. At laparotomy, the retroperi-
toneal mass was completely resected with en
bloc resection including a right nephrectomy.
Microscopic margins were negative. 
Two years following primary tumor resec-
tion, follow-up imaging detected multifocal
recurrence in the retroperitoneum and in the
lungs, complicated with thrombus within the
inferior vena cava and left femoral vein. The
patient underwent sequential chemotherapy
(prolonged infusional ifosfamide) and high-
dose palliative radiotherapy to the retroperi-
toneal and tumor bed masses.5 One year later,
he presented with multiple cutaneous lesions,
a left submandibular tumor deposit and an
incidental metastatic right cerebellar hemi-
sphere brain deposit (Figure 1). The patient
underwent palliative radiotherapy to the whole
brain and submandibular region. Three
months later, he developed rapidly progressive
neck and back cutaneous lesions; CT showed
the presence of widespread progressive dis-
ease including a new right ventricular mass
and progressing brain and submandibular
metastases. He was not eligible for a clinical
trial due to his poor performance status and
opted for best supportive care. Histopathology
Macroscopically, the primarily excised
retroperitoneal tumor was a 7.8 kg, 30×25×15
cm circumscribed lobulated mass lined by peri-
toneum on one surface and by a focally disrupt-
ed thin fibrous capsule on the opposite sur-
face. The cut surface was yellow to pale white
and firm, with approximately 20% necrosis. At
one edge there was a 6×1.5×0.5 cm unremark-
able adrenal gland. The kidney was encased by
tumor. Histologically, the tumor was a partially
circumscribed malignant neoplasm with two
components. One component consisted of
sheets of variably sized adipocytes with scat-
tered lipoblasts and fibrous septa with pleo-
morphic spindle cells, which showed atypical,
enlarged hyperchromatic nuclei. Focal fat
necrosis and infarction were present. The sec-
ond component comprised solid aggregates of
pleomorphic spindle cells in patternless distri-
butions. There was marked atypia, prominent
necrosis and a mitotic index greater than
20/10 high-power fields (HPF), including atyp-
ical forms. In places, the tumor contained mul-
tiple osteoclasts associated with epithelioid
spindle cells with variably sized ovoid nuclei,
coarse chromatin and prominent nucleoli, with
abundant amphophilic cytoplasm and incon-
spicuous cell borders (Figure 2A). Focally with-
in these areas there was dense eosinophilic
stroma, containing cells with mildly to moder-
ately atypical nuclei, with calcification and
ossification (Figure 2B), in keeping with
osteosarcomatous differentiation. In places,
the pleomorphic component infiltrated the
well-differentiated component in a pattern of
co-mingling. The tumor infiltrated the renal
capsule and focally extended beyond it within
the renal parenchyma predominantly in a
pushing growth pattern. Immunohi -
stochemically, the tumor was diffusely positive
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for CDK4 (Figure 2C) and p16. There was focal
positivity for desmin in the pleomorphic sarco-
matous component, while myogenin was nega-
tive. Amplification of the MDM2 gene at 12q15
was demonstrated by fluorescence in situ
hybridization (FISH). 
The features were consistent with well-dif-
ferentiated and dedifferentiated liposarcoma
with osteosarcomatous differentiation, grade 3
according to the French Federation of Cancer
Centres Sarcoma Group grading system. The
tumor did not infiltrate the adrenal gland or
the ureter, although focally the tumor capsule
was disrupted, with tumor present at the free
surface. 
A subsequent core biopsy of the patient’s
subcutaneous back nodule, which developed
three years following the primary resection,
showed tumor composed of highly atypical
spindle cells with multinucleate giant cells, a
mitotic index of more than 20 mitoses/10 HPF
and early infiltration of skeletal muscle
(Figure 2D). No tumoral osteoid was present.
FISH again showed amplification of the MDM2
gene at 12q15, consistent with the subcuta-
neous metastasis representing dedifferentiat-
ed liposarcoma.
Discussion
Retroperitoneal sarcomas are a heteroge-
neous group of neoplasms, mainly comprising
two sarcoma subtypes: well-differentiated/ded-
ifferentiated liposarcomas and leiomyosarco-
ma. Dedifferentiated liposarcoma occurs most
commonly within the retroperitoneum, and
accounts for the majority of spindle cell or
pleomorphic sarcomas at this site,6 and molec-
ular techniques have shown that a large pro-
portion of DDL were previously misdiagnosed
as undifferentiated pleomorphic sarcoma (pre-
viously malignant fibrous histiocytoma).7
Immunohistochemistry for CDK4, MDM2
and p16 are useful diagnostic adjuncts, helping
to distinguish WDL and DDL from other
adipocytic neoplasms in their differential diag-
nosis; these markers have been shown to be
expressed in 70% of WDL/DDL with almost
95% expressing at least two markers.8,9 WDL
and DDL characteristically contain supernu-
merary ring and/or giant chromosomes; these
contain amplicons from the 12q13-15 region
which houses proto-oncogenes including
cyclin-dependent kinase 4 (CDK4), murine
double minute type 2 (MDM2) and high-mobil-
ity AT-hook 2 (HMGA2). MDM2 is the most fre-
quently amplified gene, present in almost
100% of WDL and DDL, and CDK4 is amplified
in over 90%. Amplification of MDM2, CDK4
and HMGA2 can be detected by molecular tech-
niques including FISH and reverse transcrip-
tion-polymerase chain reaction. MDM2 ampli-
fication by FISH is a hallmark for these tumors
and is now the gold standard in the diagnosis
of WDL/DDL,10,11 although is not a specific test,
as up to 40% of other soft tissue sarcomas can
harbor MDM2 amplification.12 However, MDM2
amplification is not associated with the other
liposarcoma subtypes (myxoid and pleomor-
phic liposarcomas).10
In our case, MDM2 amplification was
demonstrated in both the primary retroperi-
toneal tumor and the subsequent subcuta-
neous metastasis. The median survival for
DDL patients with metastatic disease has been
reported in the region of 28 months, compared
                             Case Report
Figure 1. A) A partially necrotic metastatic lesion is present in the left submandibular
region, distorting the submandibular muscles and the tongue. B) There is an enhancing
right occipital nodule in keeping with a brain metastasis. No peritumoral edema was
identified. 
Figure 2. A) Dedifferentiated liposarcoma. The excision specimen from the retroperi-
toneal mass shows cellular tumor, composed of sheets of atypical spindle cells with hyper-
chromatic nuclei and moderate amounts of amphophilic cytoplasm. Prominent osteo-
clast-like giant cells are dispersed within the neoplasm (Hematoxylin and eosin). B) Ill-
defined foci of moderately cellular tumoral osteoid are present within the primary tumor,
and contain mildly atypical osteocytes, and this is in keeping with heterologous osteosar-
comatous differentiation. Mineralization is also seen. C) Immunohistochemically, the
neoplasm shows diffuse, strong nuclear expression of CDK4, consistent with the diagno-
sis of dedifferentiated liposarcoma. D) The biopsy from the subcutaneous mass shows
similar tumor, composed of atypical spindle cells with interspersed giant cells, although
tumoral osteoid is not evident in the biopsy sample. 
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to 38 months for patients without metas-
tases.13 Locoregional recurrence of WDL/DDL
represents the main cause of mortality and
disease burden, with 40-80% of patients devel-
oping recurrence after surgery.14 Metastasis of
DDL is rare; the literature mainly comprises
isolated case reports and a few case series,
with reported rates of metastatic DDL of about
1-18%.1,15,16 A recent study by Tirumani and col-
leagues reported an incidence of metastatic
disease in a series of patients with DDL of
29.76%.13 The authors suggested that this high
incidence of metastatic disease could be attrib-
utable to referral bias at their tertiary cancer
center, and potential detection bias related to
more frequent thoracic screening. Sites of
metastasis included lung in 33 (22.3%), subcu-
taneous or intramuscular soft tissue in 23
(15.5%), lymph nodes in 15 (10.1%), liver in 11
(7.4%), bone in 7 (4.7%), mediastinum in 4
(2.7%), adrenals in 3 (2.0%), and brain, thy-
roid and tongue metastasis each in one patient
(0.7%). 
The development of brain metastasis in DDL
is an exceedingly rare finding. In a retrospec-
tive study of brain metastasis in patients with
sarcoma, Shweikeh and colleagues described
nine published reports of liposarcoma metas-
tasis to the brain between 1988 and 2010.
However, these reports did not specify the
liposarcoma subtype.17 In a cohort of 3829 sar-
coma patients treated at Memorial Sloan
Kettering between 1982 and 1999, 40 soft tis-
sue sarcoma patients developed brain metasta-
sis, of whom 12.5% (5 patients) had liposarco-
ma. Similarly, this study did not specify the
liposarcoma subtype, and consequently did not
reflect the exact prevalence of brain metas-
tases in DDL.
There are few published studies evaluating
potential predictive factors of metastasis in
DDL. In a study of retroperitoneal sarcomas,
Toulmonde and colleagues confirmed the
impact of histologic grade on survival of DDL.18
Tirumani and colleagues also found a statisti-
cally higher incidence of metastases in high
grade DDL,13 but in contrast a prior study of
155 patients by Henricks and colleagues
reported no relationship between histologic
grade and the risk of metastases.1 Tirumani
and colleagues also observed that the presence
of local recurrence correlated with a statistical-
ly increased risk of distant metastasis, while
earlier studies noted the presence of distant
metastases in the absence of recurrence. The
size of the primary tumor, number of surgical
resections, involved surgical margins or
administration of chemoradiation had no
influence on the development of metastatic
disease.13,16
Although there are no established predictive
factors of DDL metastasis, in our patient we
note specific characteristics of the primary
tumor which differ from those seen in most
retroperitoneal DDL, which we speculate may
have contributed to its unusually aggressive
behavior: i) it was a grade 3 sarcoma, in con-
trast to most retroperitoneal DDL which in our
experience have relatively fewer mitoses and
smaller amounts of necrosis than other pleo-
morphic sarcomas and tend to be more fre-
quently grade 2 neoplasms; ii) there was focal
osteosarcomatous differentiation in the pri-
mary tumor but not in the core biopsy of the
subcutaneous metastasis, raising the question
as to whether there might be a link between a
heterologous high-grade sarcomatous compo-
nent and the risk of metastasis. A recent study
has shown that retroperitoneal liposarcomas
with myogenic differentiation (particularly
those with a rhabdomyoblastic component)
have a significantly worse outcome;19 iii) the
tumor showed histologic infiltration of the kid-
ney capsule and renal parenchyma, in contrast
to most retroperitoneal WDL/DDL which tend
to encase but not infiltrate the parenchyma of
retroperitoneal organs. Early infiltration of
skeletal muscle was also noted in the core
biopsy of the subcutaneous metastasis, high-
lighting the unusually infiltrative behavior of
this neoplasm.
Conclusions
In conclusion, we reported a case of MDM2-
amplified retroperitoneal dedifferentiated
liposarcoma with lung, subcutaneous and
brain metastases. Metastasis of DDL outside
the abdominal cavity is rare, and brain metas-
tasis is exceptional. Because prior series of
metastatic liposarcomas have typically not sub-
classified neoplasms into precise subtypes, we
highlight the importance of documentation of
this rare phenomenon, including the potential
reasons for its unusual behavior. Further large
studies of stringently diagnosed DDL are
required to better understand their biologic
behavior and to determine the factors related
to metastases for this heterogeneous liposar-
coma subtype. 
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